The objective of this study was to develop a screening process for the analysis of sexual assault samples. Recently, the Society of Forensic Toxicologists created a committee to address the issue of drug-facilitated sexual assault (DFSA) in the toxicology field. This committee prepared a list of drugs that could be, or have been, used in DFSAs. The list comprises about 50 compounds, including illicit, prescription, and over-the-counter drugs. Using this list, our laboratory wanted an easy, fast, and sensitive method to analyze a urine sample for all 50 of these drugs. We screened and confirmed for 20 compounds, including cocaine, amphetamines, benzodiazepines, barbiturates, opiates, methadone, alcohol, and PCP. A gas chromatographic-mass spectrometric screening method that was able to detect the remaining 30 compounds following 1 extraction and using only 2 mL of urine was developed. The process is inexpensive and uses equipment available in most forensic toxicology laboratories. This method is recommended for any laboratory that commonly receives specimens collected from sexual assault victims and is interested in a more thorough analysis.
Introduction
In 2000, 90,186 rapes were reported to law enforcement, according to the FBI Uniform Crime Reports. This is equivalent to 32 per 100,000 inhabitants, or roughly 64 per 100,000 females (1) . Of the relatively few reported drug-facilitated sexual assaults (DFSA), the perpetrator is often not arrested. In fact, the clearance rate nationwide is only 46.9%, and many of the individuals arrested for these crimes are never convicted (1) .
The use of drugs in sexual assault is an increasing problem (2-4). It is not precisely known how often drugs are used to facilitate rape, but both alcohol and illicit drugs have been detected in a large percentage of urine samples collected from sexual assault victims (5) . It has been shown that individuals who use drugs with or without alcohol are at a significantly higher risk for sexual assault (6) . In some cases, the substances are taken voluntarily by the victims, impairing their ability to make decisions. In other cases, the substances are given to the victims surreptitiously, decreasing their ability to identify the threat of an assault or to resist the perpetrator. A number of the substances used to facilitate sexual assaults impair the victim's memory as well as his/her decision-making ability (2, 7) .
Finding an illicit drug in the sexual assault victim's system would be very beneficial to the successful prosecution of the guilty party. By law, an individual incapacitated by drugs or alcohol is unable to consent to sexual intercourse whether the substances were taken voluntarily or otherwise. In addition, the U.S. Drug-Induced Rape Prevention and Punishment Act enacted in 1996 increased the penalties (up to 20 years in prison) for anyone who surreptitiously gives someone a drug with the intent to sexually assault him/her. Without a doubt, the ability of law enforcement agencies to detect and identify all substances that the victim had consumed prior to the alleged assault is critical for their ability to prosecute this type of crime. Unfortunately, many factors make the detection and identification of all potential date-rape drugs difficult at this point in time.
Currently, there is no known estimate of the number of drug-facilitated sexual assaults that take place every year. There have been plenty of anecdotal evidence and news reports (8) (9) (10) (11) on DFSA, but no scientific study has been conducted to examine this problem. Previous studies by ElSohly and Salamone (5) and Slaughter (6) have examined the prevalence of "date-rape" drugs among sexual assault victims from across the country. Slaughter's work (6) showed that two-thirds of the samples collected (N = 2003) were positive for alcohol and/or drugs. EISohly and Salamone's research (5) was done on 1179 samples, and 60.3% of their samples tested positive for at least one drug. The two best-known "date-rape" drugs, GHB and flunitrazepam, were found in less than 4% of the samples for both studies. These studies were limited because only samples from victims that had a history of drug abuse or who claimed they were sexually assaulted after being given a drug were accepted. This does not examine the prevalence of DFSA, only the prevalence of DFSA among a select part of the population.
Our research presents a more unbiased view of DFSA because we did not discriminate between which sexual assault victims were accepted.
The chosen analytical techniques and scope of analytes for the previous studies had several limitations. E1Sohly and Salamone's work (5) involved an OnLine immunoassay for amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, methaqualone, opiates, PCP, and propoxyphene. This was followed by specific gas chromatographic-mass spectrometric (GC-MS) assays for flunitrazepam and GHB and a gas chromatographic-flame-ionization detection (GC-FID) method for the detection of alcohol (5) . All of Slaughter's samples were sent to E1Sohly for analysis following this same technique (6) . Although this scheme will detect major drugs of abuse, many other compounds that could incapacitate someone will not be detected. Some over-the-counter and prescription medicines have pharmacological properties that make them ideal "date-rape" drugs. These compounds are also easier to obtain than illegal drugs and thus their use could be rampant. However, both previous studies would have been unable to verify if their use is a problem among sexual assault victims.
Recently, the Society of Forensic Toxicologists created a committee to address the issue of DFSA in the toxicology field. This committee prepared a list of drugs that could be, or have been, used in DFSA. Our laboratory wanted to develop an analytical procedure to screen for these 50 different compounds that could be employed by any toxicological laboratory that received samples from sexual assault victims. Minimizing the amount of sample used was of paramount importance because the volume of specimen received can vary widely for each victim. United States Drug Testing Laboratory (USDTL), was able to screen and confirm for 20 compounds including cocaine, amphetamines, opiates, PCP, marijuana, ethanol, some benzodiazepines, some barbiturates, and methadone. The group of 30 additional drugs (Table I ) has many corn- pounds for which an easy screening method has not already been developed. Our task was therefore to develop a screening process for these 30 compounds. Using a modified version of an extraction method provided to us by United Chemical Technologies (UCT), we were able to develop a screening method that used only 2 mL of urine and could screen for 30 compounds. This method is easy to use and is recommended for any laboratory interested in finding drugs that could be used to incapacitate someone for the purpose of sexually assaulting him/her.
Experimental

Subjects and specimens
The study is currently being conducted in four hospitals nationwide ( Figure 1 ). When a sexual assault victim presents, the nurse who treats the patient asks him or her if they are interested in participating in our study. If the victim agrees, they are told of the risks present in this study and asked to provide an initial visit urine sample and answer a brief questionnaire. The victim is then asked to return to the hospital in one week to provide a second urine sample and a hair sample, and they are financially compensated for any expenses that they may incur. All supplies that are needed for each visit have been provided to the hospitals by our laboratory and include pre-addressed UPS boxes that ensure the urine samples arrive at our laboratories as quickly as possible.
This study was reviewed and approved by the University of Illinois at Chicago Institutional Review Board and the Institutional Review Boards at each of the collaborating sites.
Analysis of commonly abused drugs
USDTL received an aliquot of each urine sample. Urine samples were screened using an enzyme multiplied immunoassay technique (EMIT) for amphetamines, carboxy-THC, opiates, phencyclidine, benzoylecgonine, oxazepam, methadone, barbiturates, and ethanol. All presumptive positive samples were then confirmed by GC-MS following standard urine drug testing protocols. Results for the analysis of marijuana, cocaine, opiates, benzodiazepines, and amphetamines by USDTL are presented in Figure 2 .
Instrumentation for GC-MS screen
The GC-MS system consisted of a Hewlett-Packard 6890 series injector, an HP 6890 series GC system, and an HP 5973 operating with electron-impact ionization (Wilmington, DE). An HP-5MS capillary column (30 m x 250 lJm x 0.25 ]Jm) was used for separation. The heating block and vacuum oven model 5831 (Napco | were purchased from Fisher Scientific (Itasca, IL). The Vac-Elut TM extraction manifold was from Analytical International (Varian, Harbor City, CA), and the centrifuge model 5810 (Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany) was acquired from Brinkmann Instruments, Inc. (Westbury, NY). The Meyer N-EVAP | analytical evaporator was purchased from Organomation Assoc., Inc. (Northborough, MA), and the Aerograph water bath sonicator was purchased from Varian (Harbor City, CA).
Chemicals and reagents
Doxylamine succinate (1 mg/mL), norfluoxetine HCI (1 mg/mL), desipramine HCI (1 mg/mL), carisoprodol (1 mg/mL), and cyclobenzaprine HCI (I mg/mL) were purchased from Alltech (State College, PA). Norketamine HC1 (1 mg/mL), 7-aminoflunitrazepam (1 mg/mL), 7-aminoclonazepam (1 mg/mL), alprazolam (1 mg/mL), hydromorphone (1 mg/mL), meprobamate (1 mg/mL), chlorpheniramine maleate (1 mg/mL), diphenhydramine HC1 (1 mg/mL), doxepin (1 mg/mL), amitriptyline (1 mg/mL), butalbital (1 mg/mL), oxycodone (1 mg/mL), triazolam (1 mg/mL), hydrocodone (1 mg/mL), paroxetine maleate (1 mg/mL), chlordiazepoxide (] mg/mL), nortriptyline (1 mg/mL), dextromethorphan (] mg/mL), clonidine (1 mg/mL), imipramine (1 mg/mL), and amobarbital (1 mg/mL) were purchased from Cerilliant Corporation (Round Rock, TX). Citalopram (1 mg/mL), scopolamine (1 mg/mL), valproic acid (1 mg/mL), zolpidem (1 mg/mL), and sertraline (1 mg/mL) were purchased from Utak Laboratories (Valencia, CA). Methanol (HPLC grade), glacial acetic acid (HPLC grade), methylene chloride (HPLC CCCll.l
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Controls
The 30 compounds were split into 2 groups of 15 each, named A and B. ~vo spiked urines (A and B) were run each analysis day and contained all of the compounds being analyzed. Each compound was spiked in the urine at a concentration of 1 pg/mL and verified that it was still being detected. Table II shows each drug along with its limit of detection and which ions are being monitored. Figures 3 and 4 are representative chromatograms for each of the two spiked urines showing relative retention times for the compounds being screened.
Analytical procedure
Using 2 mL of the victim's urine, the extraction process begins with the cleavage of any glucuronide conjugates by 50 pL of [3-glucuronidase and 1.0 mL of ammonium acetate (pH 4.5). The cleavage is done in capped test tubes at 37~ for 60 min. Following enzyme cleavage, 3.0 mL of a 0.1M sodium phos- phate (dibasic, pH 9) solution is added to the urine. The extraction columns are then prepared prior to addition of the sample. First, 3.0 mL of methanol is added to each column and allowed to flow through the column. Next, 3.0 mL of water is added, followed by 1.0 mL of 0.1M sodium phosphate (dibasic, pH 6.0). Care is taken in these preparatory steps to not allow the columns to dry, as this will negatively affect the resulting chromatography. The samples are then added to the columns and allowed to flow through at about 1-2 mL/min. This allows sufficient time for all of the compounds to bind to the column. 
Chromatographic method
The injector was operated in the splitless mode at 250~ and the injection volume was 1 t~L. Ultra high purity helium (99.999%) was used as the carrier gas at a flow rate of 1.2 mL/min. The initial GC oven temperature of 100~ was held for 1 rain, and then increased at a rate of 20~ until the final temperature of 310~ was attained. The final temperature was held for 3 rain. The total run time for one injection was 14.50 rain. The MS ion source temperature was 230~ and the quadrupole temperature was 150~ The mass selective electron ionization detector was operated in selected ion monitoring (SIM) mode. The solvent delay was 6.35 rain. Three ions were monitored for each compound near to the retention time of the respective compound. The dwell time for all ions was 20 ms.
A complicated SIM method was formulated to further enhance the sensitivity of the screening process. T~venty-five SIM groups were constructed with each group scanning for one to three different compounds (i.e., three to nine different ions). The amount of background noise was decreased because all 90 ions are not being scanned throughout the entire runtime. This SIM method also helps the library search return fewer false positives and thus decrease post-analysis sample processing. Table III 
Results
Figures 3 and 4 are representative chromatograms for each of the spiked controls showing the relative retention times of the compounds. All 30 compounds were able to be detected by our method. After running each compound separately, a GC-MS library was constructed to aid in the analysis of our GC-MS screens. Each compound was entered into the library with its corresponding SIM mass spectrum. After a victim's sample was analyzed, a library search report that detailed what drugs have been found and at which retention times was printed. Each found compound was then compared to that day's spiked sample to determine if the retention times were in agreement. If the retention times matched, the SIM mass spectrum of the sample was then compared with the known SIM mass spectrum to determine if the ion ratios were in agreement and thus insure that the library search report was indeed correct. The spiked controls helped to take into account any daily chromatographic variations that may occur and thus decrease the amount of false positives. The limits of detection for each compound as indicated in Table II are based on a signalto-noise ratio of 3:1. Currently, 106 urine samples collected from sexual assault victims have been screened using this method ( Figure 5 ).
USDTL has screened and confirmed 125 urine samples for the commonly abused drugs. This does not represent 125 unique patients, but rather 90 unique patients with 35 returning to the hospital for the second visit. Figure  2 shows the results of the analysis of these 125 samples for marijuana, cocaine, opiates, benzodiazepines, and amphetamines by USDTL as well as the percent of samples that were positive for the different drugs.
Discussion
Our laboratory is still receiving samples from complainants of sexual assault, and we will continue to analyze them following the process described in this paper. Another method that will be able to screen for GHB and valproic acid, two compounds that were unable to be detected by this screening process, is still being developed. Confirmations will also be done on all presumptive positive samples following standardized or previously published methods. However, if any compounds have not been previously confirmed by GC-MS, our laboratory will develop new GC-MS methods for these compounds. We are cognizant of the fact that some of the victims may have only received one dose of the drug and will have very low levels of the drug or metabolite in their urine. Thus, NCI-GC-MS will be employed for confirmations whenever possible because of its increased sensitivity. (12) . Table IV shows that women involved in a sexual assault were more likely to have consumed drugs than the average woman. These results strengthen the commonly held notion that drugs that alter one's perception place an individual at a higher risk of being the victim of a crime. Figure 5 demonstrates that prescription and over-thecounter drugs are also commonly found in the urine of sexual assault victims. Of the 126 victims currently screened, over 69% have been presumptively positive for at least one drug and 44% have been positive for more than one drug. Once all samples have been received and screened by this process, confirmations will be done for each compound. The prevalence of these 30 compounds will then be calculated and compared to the prevalence of the common drugs of abuse. This will help forensic toxicologists determine if the analysis for all 50 compounds is necessary when working with specimens from sexual assault victims.
An analytical procedure for the detection of 50 drugs and/or their metabolites as described in this paper, along with better coordination between Sexual Assault Nurse Examiners, law enforcement officials, and forensic toxicologists, could dramatically improve the ability to detect drugs used in DFSA cases. This, in turn, could increase the success with which these difficult cases are prosecuted. An improvement of the conviction rate might en- Figure 5 . GC-MS screening results for "date-rape" drugs.
courage more victims to report these assaults while discouraging potential rapists from committing these crimes.
Conclusions
This paper is the initial stage in the development of a process to analyze specimens from sexual assault victims. Because of the lack of conformity among toxicology laboratories, we are trying to develop a systematic method that could be employed when a laboratory receives a sexual assault specimen. The first part, the screening process, is the most critical because all further analyses will be based on the results from the initial screen. We were also sensitive to the fact that sample size can become the limiting factor during an analysis, and thus we wanted a process that would be robust, but not consume too much of the sample. The process developed in this paper is able to screen for 60 compounds using only 2.5 mL of urine. The method is inexpensive and relies on commonly used extraction procedures that are routine in the toxicology field. By choosing GC-MS, we have selected the instrument most used by forensic toxicologists, and therefore, all laboratories should be able to do the analysis. The developed methodology can be applied to urine samples collected from victims of sexual assault when the surreptitious use of drugs is suspected.
